August 2026 Research Update

This month added more human evidence that disease-modifying treatments in ATTR cardiomyopathy are linked to meaningful differences in longer-term outcomes and heart function measures, but the new findings come from different kinds of studies that answer different questions. A large real-world comparison reported better survival in people treated with tafamidis than in similar untreated people. A separate analysis from a randomized trial reported that vutrisiran slowed worsening in a specific heart ultrasound measure related to the left atrium, a heart chamber often affected in ATTR-CM. [1] [2]

In routine care data from 2019 to 2023, patients with ATTR-CM who received tafamidis had higher estimated survival at 30 and 42 months than matched patients who did not receive tafamidis, and no new safety signals were reported in this dataset. Because this was not a randomized comparison, it cannot prove why the difference occurred, but it strengthens the picture that tafamidis-treated groups can do better than similar untreated groups in real-world settings. [1]

From the HELIOS-B randomized trial population (predominantly wild-type ATTR), left atrial strain abnormalities were common and were linked to higher risk of death and cardiovascular events over time, while a different left atrial size measure was not. Vutrisiran (an RNA-targeting treatment) reduced the amount of worsening in left atrial strain over 30 months compared with placebo, suggesting this heart function measure can change more slowly on treatment in this trial setting. [2]

A new phase 4 study called ACO-SWITCH will follow 50 adults with variant or wild-type ATTR-CM for 6 months after switching from tafamidis to acoramidis, another transthyretin stabilizer. The main planned outcome is change in blood transthyretin levels, with additional heart, kidney, thyroid, imaging, walking, and quality-of-life measures, but results are not available yet. For now, this study mainly signals that the field is actively studying what switching looks like in a structured way. [3]

For patients, these studies mainly add to the evidence base about ATTR-CM treatments rather than changing anything immediately. The tafamidis report may matter now because it describes survival differences seen in real-world care, while the vutrisiran analysis may matter now because it links a heart ultrasound measure (left atrial strain) to later outcomes and shows it worsened more slowly on active treatment in a randomized trial. The switching study matters more for the future, because it does not yet report whether switching from tafamidis to acoramidis changes blood markers, symptoms, or heart measures over 6 months. [1] [2] [3]

A practical point these studies highlight is that different measures may be used to track ATTR-CM: survival in routine care datasets, heart chamber function on ultrasound in trials, and blood transthyretin levels in switching studies. What remains uncertain is how well changes in any one marker reflect how a person feels and functions, and how to compare results across different treatments when the studies are not designed head-to-head. [2] [3] [1]

This month made it clearer that living with wild-type ATTR often involves more than the heart, and that common lab markers do not always map neatly onto symptoms or day-to-day well-being. A neurology follow-up study found many people with ATTRwt cardiomyopathy had signs of mixed nerve involvement and frequent carpal tunnel syndrome, with only subtle changes over about a year. A quality-of-life study reported high levels of distress and reduced physical and mental health, driven most strongly by fatigue and functional limits rather than by heart imaging measures of amyloid load. [4] [5]

In a prospective assessment of 23 adults with ATTRwt cardiomyopathy, most had testing consistent with large-fiber nerve involvement, and nearly half had evidence of reduced small nerve fibers on skin biopsy compared with controls. Carpal tunnel syndrome was especially frequent and often occurred together with polyneuropathy, while follow-up testing showed no rapid worsening on nerve conduction studies and only small average changes in a neuropathy score over about 13 months. This supports the idea that nerve symptoms can be common in ATTRwt-CM and may change slowly over short follow-up periods, though the study was small. [4]

In the AmyKoS cohort of 110 analyzable adults with systemic ATTRwt, most participants reported reduced quality of life and many screened positive for distress, with about a quarter screening positive for anxiety and/or depression. Across questionnaires, fatigue and functional limitation were consistent predictors of psychological burden, while several heart imaging measures of amyloid load (such as wall thickness and strain) were not linked to these mental health outcomes. This suggests that how a person feels day-to-day may be influenced more by energy level, breathlessness, sleep, and independence than by certain imaging markers alone. [5]

Two other studies helped clarify how clinicians and researchers interpret blood markers in ATTR-CM. A cohort of 441 newly diagnosed ATTR-CM patients in the tafamidis era found that the NAC stage and a modified Mayo stage separated survival similarly, while an extended NAC approach identified a smaller group with very high mortality risk. Separately, a longitudinal cohort measuring blood transthyretin levels showed that transthyretin levels moved up or down with age, inflammation, cardiac stress, nutrition-related markers like albumin, and with different disease-modifying treatments, meaning a single transthyretin number does not act as a simple readout of how severe the disease is. [6] [7]

In the 441-person prognostic staging study (94% wild-type and 85% on tafamidis), 3-year survival differed clearly across stages for both the NAC and modified Mayo systems, showing these blood-marker-based stages remain useful for separating higher- and lower-risk groups even in a modern treatment era. The extended NAC approach added a stage IV group with lower 3-year survival, highlighting that some newly diagnosed patients still present with very advanced disease biology despite access to treatment. This kind of staging research focuses on risk grouping, not on predicting what will happen to any one individual. [6]

In the 134-person cohort tracking transthyretin in the blood over time, higher inflammation and higher cardiac stress markers were linked to lower transthyretin levels, while wild-type status and higher albumin were linked to higher levels. Transthyretin stabilizers increased blood transthyretin, while siRNA therapy lowered it, and levels rose over longer time on stabilizers. Together, these findings argue that blood transthyretin reflects overall body state and treatment effects as much as it reflects amyloid disease itself. [7]

For patients and caregivers, these studies add clarity about what ATTRwt can look like in real life and how tests are interpreted, rather than pointing to a new treatment decision. The nerve study suggests that carpal tunnel syndrome and other nerve problems can be common in ATTRwt-CM and may not always progress quickly over about a year, which may help people understand why symptoms can be present even when change feels slow. The quality-of-life study underscores that fatigue, breathlessness, sleep problems, and loss of independence can strongly shape emotional well-being, even when certain heart imaging markers do not line up with distress levels. [4] [5]

The staging and biomarker work may matter now mainly as context for understanding lab results. Staging systems based on heart-related blood markers continued to separate groups with better versus worse survival in a large modern cohort, while blood transthyretin levels were shown to shift with inflammation, nutrition, and the type of therapy someone is on. What remains uncertain is how best to combine symptom tracking, functional tests, imaging, and blood markers into a single picture that matches an individual person's experience. [6] [7]

This month included several single-patient reports that, taken together, emphasize a recurring real-world challenge in wild-type ATTR: test results, eligibility rules, and imaging markers may not perfectly reflect symptoms and function. One case used exercise testing to show meaningful functional limits despite a low NT-proBNP that blocked tafamidis reimbursement, leading to expanded-access acoramidis and improved exercise capacity at 6 months. Another case showed a large drop in a heart scan amyloid signal while symptoms and some other measures worsened, raising questions about how to interpret imaging changes over time. [8] [9]

In one patient, amyloid found incidentally in the left atrial appendage during surgery led to workup that confirmed wild-type ATTR cardiac amyloidosis. After starting tafamidis and other management, he remained clinically stable at 1 year. This case highlights that atrial tissue findings can sometimes uncover previously unrecognized ATTR-CM. [10]

In the CPET-guided access case, the patient had NT-proBNP (a heart-strain blood test) below the reimbursement threshold of 600 pg/mL yet had impaired functional capacity on cardiopulmonary exercise testing. After receiving acoramidis through expanded access, he was reported clinically stable with improved exercise capacity at 6 months. As a single case, it cannot show what will happen for most people, but it illustrates why function testing and biomarker thresholds may sometimes point in different directions. [8]

In the quantitative Tc-PYP imaging case, a patient on tafamidis showed a marked decrease in tracer uptake and volumetric imaging indices over about 18 months, while symptoms and some other markers suggested decline. This reported mismatch suggests that changes in one imaging marker might not always mirror changes in day-to-day symptoms for an individual patient, and it supports the idea of looking at multiple measures when following disease course. [9]

One exploratory computational study built a machine-learning model to predict which chemical structures might bind transthyretin, then used it to screen a database of food-derived compounds. The output prioritized a set of mostly polyphenol-rich compounds as candidates for future lab testing, but there were no patient results and no direct experimental validation in this report. This work is best understood as early-stage hypothesis generation rather than evidence that any food compound affects ATTRwt in people. [11]

For patients, the case reports mainly help explain why follow-up in ATTRwt can feel confusing: biomarkers, scans, and symptoms may not always move together. These reports may matter now as context for understanding how some eligibility rules or single test results could miss important functional limitations in an individual, and why a single imaging change might not capture overall health. Because these are single-patient observations, they do not predict what will happen for most people. [8] [9] [10]

The computer-based compound screening is early research that may matter later if laboratory and clinical studies confirm any real biological effect. For now, it does not show that any specific food or supplement changes transthyretin amyloidosis in people, but it does show how researchers are trying to broaden the set of molecules that could be tested as transthyretin binders in the future. [11]